All In Biotech

Drug Trial Radar · NCT06608901

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN7544, an Antagonist Monoclonal Antibody to NPR1, in Patients With Sepsis-Induced Hypotension

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

May 5, 2025

Primary completion

Feb 1, 2026

Study completion Apr 28, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Sep 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during the stay in the hospital. The study is looking at several other research questions, including: * How the study drug changes the blood pressure and the amount of intravenous (IV) fluids given to participants with low blood pressure due to sepsis * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Sepsis-Induced Hypotension

Interventions

  • REGN7544Drug

    Administered per the protocol

  • PBDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative vasopressor doseTime frame: Through 72 Hours

Locations

29 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

  • Yale University

    New Haven, Connecticut

  • Emory University Hospital

    Atlanta, Georgia

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Harvard Medical School - Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • New York University Langone Health Brooklyn Hospital

    Brooklyn, New York

  • Bellevue Hospital

    New York, New York

  • New York University Langone Health Tisch-Kimmel Hospital

    New York, New York

  • Montefiore Medical Center - Weiler Hospital

    The Bronx, New York

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York

  • Atrium Health

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • MUSC SCTR Research Nexus Clinic and Lab

    Charleston, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Intermountain Medical Center - Murray (Pulmonary Medicine)

    Murray, Utah

  • Centre Hospitalier Universitaire Angers

    Angers, France

  • Raymond Poincare University Hospital

    Garches, France

  • Paris-Saclay University Hospitals

    Le Kremlin-Bicêtre, France

  • CHU Nantes

    Nantes, France

  • Centre Hospitalier Universitaire d'Orleans

    Orléans, France

  • CHU de Reims Hopital Robert Debre

    Reims, France

  • Hopitaux Universitaires de Strasbourg

    Strasbourg, France

  • Hopital Nord Franche Comte

    Trévenans, France

  • Centre Hospitalier Regional Universaitaire de Tours (CHRU de Tours)

    Tours, Centre-Val de Loire, France

  • Hopital Cochin

    Paris, Île-de-France Region, France

  • CHU Dupuytren

    Limoges, New Aquitaine, France

  • Centre Hospitalier Le Mans

    Le Mans, Pays de la Loire Region, France

  • Centre Hospitalier Departemental (CHD) Vendee

    La Roche-sur-Yon, Vendee, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.